Products for Research Use Only
RegisterLogin

PF-543

CAT: 0804-HY-15425-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15425-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 is >100-fold selectivity for SPHK1 over SPHK2. PF-543 is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 induces apoptosis, necrosis, and autophagy[1][2][3].
CAS Number
1415562-82-1
Product Name Alternative
Sphingosine Kinase 1 Inhibitor II
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; LPL Receptor; SphK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; GPCR/G Protein; Immunology/Inflammation
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/PF-543.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(OCC2=CC=C(CN3[C@@H](CO)CCC3)C=C2)=CC(CS(C4=CC=CC=C4)(=O)=O)=C1
Molecular Formula
C27H31NO4S
Molecular Weight
465.60
Precautions
H302, H315, H319, H335
References & Citations
[1]Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444 (1) :79-88.|[2]MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28 (8) :946-55.|[3]Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SphK1
Citation 01
Arch Pharm Res. 2025 Aug;48 (7-8) :798-813.|Cancer Commun (Lond) . 2025 Jul 16.|Cancer Sci. 2020 Jul;111 (7) :2259-2274.|Cell Death Dis. 2024 Aug 1;15 (8) :552.|Curr Res Pharmacol Drug Discov. 2025 Jan 9:8:100212.|Dig Dis Sci. 2025 Jun 5.|Environ Pollut. 2025 Jul 16:383:126846.|Hum Cell. 2020 Jan;33 (1) :57-66.|Inflammation. 2021 Dec;44 (6) :2170-2179.|Pflugers Arch. 2025 Jun;477 (6) :815-826.|Phytomedicine. 2025 Sep 19:148:157271.|Phytother Res. 2025 Aug;39 (8) :3419-3431.|Ren Fail. 2025 Dec;47 (1) :2568972.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.|Sci Rep. 2020 Aug 14;10 (1) :13834.|FASEB J. 2024 Jan 31;38 (2) :e23417.|Mol Cell. 2020 Mar 19;77 (6) :1294-1306.e5.

Related Products

CatalogName
HY-125327YM-543
HY-108590-01DMP-543
HY-W953122CRBN ligand-543
HY-W800770MB 543 DBCO
HY-P5396GAD65 (524-543)
HY-RI01626-01Hsa-miR-543 inhibitor
HY-P5396A-01GAD65 (524-543) (acetate)
HY-R01626A-01Hsa-miR-543 agomir
HY-R01626-01Hsa-miR-543 mimic
HY-RI01626A-01Hsa-miR-543 antagomir

Alternative Products

CatalogName
A3717-5.1PF-543
A3718-50PF-543 Citrate
A13039-1PF-543 1mg
bs-83079C-01PF-543 HCl
M23767-01PF-543 hydrochloride

Popular Products